Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment

Bisson, Jonathan Ian ORCID: https://orcid.org/0000-0001-5170-1243 2007. Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment. Evidence-Based Mental Health 10 (4) , p. 118. 10.1136/ebmh.10.4.118

Full text not available from this repository.

Abstract

Q. Is eye movement desensitisation and reprocessing more effective than fluoxetine in people with post-traumatic stress disorder? Design: Randomised controlled trial. Allocation: Concealed. Blinding: Double blind. Follow-up period: Eight months (2 months’ treatment plus 6 months’ post-treatment follow-up). Setting: Recruitment via newspaper ads, the Internet, and from medical and mental health professionals, USA; July 2000 to July 2003. Patients: 88 people aged 18–65 years old with current posttraumatic stress disorder (PTSD) (DSM-IV) and mixed trauma exposure at least one year before enrolment. Main exclusions: contraindication to study treatments, previous use of study treatments, Global assessment of functioning score ,40, unstable medical comorbidity, psychotic or bipolar disorder, alcohol or substance abuse, high risk of suicide, ongoing trauma focused treatment, unstable living arrangements, involvement in traumarelated lawsuit, or receiving disability compensation for PTSD. Intervention: EMDR, fluoxetine (dose titrated to 60 mg/day as tolerated; mean dose 30 mg/day), or pill placebo for eight weeks. EMDR was aimed at memories of the primary trauma, and involved individual weekly 90-min sessions with trained clinicians, based on specially developed treatment manuals. Outcomes: PTSD symptoms (clinician-administered PTSD Scale (CAPS), DSM-IV version; higher score indicates greater symptoms severity); asymptomatic function (CAPS score ,20); PTSD diagnosis (Structured Clinical Interview for DSM-IV Axis I and Axis II Disorders); depressive symptoms (Beck Depression Inventory-II (BDI-II)). Patient follow-up: 86% completed treatment (100% included in post-treatment analyses), 66% completed follow-up (84% included in follow-up analyses).

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects:	R Medicine > R Medicine (General)
Publisher:	BMJ Publishing Group
ISSN:	1362-0347
Last Modified:	24 Oct 2022 11:34
URI:	https://orca.cardiff.ac.uk/id/eprint/48606

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item